Table 2.
Patient characteristics
| Characteristics | n (%) |
|---|---|
| Age, y | |
| ≥ 50 | 48 (68.6) |
| < 50 | 22 (31.4) |
| Gender | |
| Male | 59 (84.3) |
| Female | 11 (15.7) |
| Therapeutic modalities | |
| SBRT alone | 20 (28.6) |
| SBRT+TACE | 46 (65.7) |
| SBRT+Surgery | 4 (5.7) |
| Dose, Gy | |
| ≤ 35.0 | 29 (41.4) |
| ≥ 40.0 | 41 (58.6) |
| Types of PVTT | |
| II | 42 (60.0) |
| III | 27 (38.6) |
| IV | 1 (1.4) |
| HBsAg | |
| Negative | 12 (17.1) |
| Positive | 58 (82.9) |
| Child-Pugh classification | |
| A | 45 (64.3) |
| B | 24 (34.3) |
| C | 1 (1.4) |
| PS (ECOG) | |
| 0 | 56 (80.0) |
| 1 | 14 (20.0) |
| Origination of PVTT | |
| Right branch | 49 (70.0) |
| Left branch | 21 (30.0) |
| AFP, ng/L | |
| ≤ 20 | 13 (18.6) |
| 21 ~ 399 | 17 (24.3) |
| ≥ 400 | 40 (57.1) |
| PLT, 109/L | |
| ≥ 100 | 39 (55.7) |
| < 100 | 31 (44.3) |
| HGB, g/L | |
| ≥ 120 | 42 (60.0) |
| < 120 | 28 (40.0) |
| TBIL, μmol/L | |
| ≥ 20 | 34 (48.6) |
| < 20 | 36 (51.4) |
| Albumin, g/L | |
| ≥ 35 | 41 (58.6) |
| < 35 | 29 (41.4) |
| ALT, U/L | |
| ≥ 50 | 25 (35.7) |
| < 50 | 45 (64.3) |
| AST, U/L | |
| ≥ 50 | 48 (68.6) |
| < 50 | 22 (31.4) |
Abbreviations: SBRT Stereotactic body radiotherapy, Types types of tumor thrombi, HBsAg Hepatitis B surface antigen, PS Performance status, ECOG Eastern Cooperative Oncology Group, AFP Alpha–fetoprotein, PLT Platelet, HGB Hemoglobin, TBIL Total bilirubin, ALT Alanine aminotransferase, AST Aspartate aminotransferase